EWP
TXG icon

Elevation Wealth Partners’s 10x Genomics TXG Stock Holding History

Elevation Wealth Partners’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$76.3K Sell
844
-643
-43% -$37.6K 0.02% 259
2026
Q2 		$57K Buy
1,487
+1,143
+332% +$30K 0.02% 274
2026
Q1 		$7.3K Buy
344
+79
+30% +$1.58K ﹤0.01% 597
2025
Q4 		$4.32K Buy
265
+51
+24% +$770 ﹤0.01% 667
2025
Q3 		$2.5K Buy
+214
New +$2.79K ﹤0.01% 604

Other funds holding TXG

VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
WPC
Wedmont Private Capital West Chester, Pennsylvania $4.18B AUM 18.65% 1-Year Est. Return
GAA
Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
GA
GoalVest Advisory New York $578M AUM 17.41% 1-Year Est. Return

Elevation Wealth Partners's TXG Position: Q3 2026 in Review

Elevation Wealth Partners reduced its 10x Genomics (TXG) stake by 43% in Q3 2026, selling an estimated $37.6K and leaving 844 shares worth $76.3K. The position accounts for 0.02% of the portfolio, ranked #259.

Elevation Wealth Partners first reported a position in TXG in Q3 2025 and has held it in 5 quarters since. 9 funds tracked by Wall St. Rank hold TXG as of Q3 2026.

  • Elevation Wealth Partners held 844 shares of 10x Genomics worth $76.3K as of Q3 2026.
  • Elevation Wealth Partners sold 643 10x Genomics shares in Q3 2026, an estimated $37.6K.
  • 10x Genomics made up 0.02% of Elevation Wealth Partners's portfolio in Q3 2026, its #259 holding.
  • Elevation Wealth Partners first reported a position in 10x Genomics in Q3 2025 and has held it in 5 quarters since.
  • 9 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2026.

Based on Elevation Wealth Partners's 13F filing for Q3 2026, filed 7 Oct 2026.